

News Release

No. 23012

June 28, 2023

Noile-Immune Biotech, Inc.

<https://www.noile-immune.com>

Notice of Listing on the Tokyo Stock Exchange Growth Market

We are pleased to announce that Noile-Immune Biotech, Inc. (Head Office: Minato-ku, Tokyo, CEO: Koji Tamada, Security Code: 4893) was newly listed on the Tokyo Stock Exchange Growth Market on June 28, 2023.

On this occasion, we would like to express our gratitude to all the stakeholders for their continuous support and trust in us.

We have been on a mission to "Create the Future to Overcome Cancer," and engaged in R&D of novel cancer immunotherapies such as CAR-T and TCR-T for solid cancer, employing our PRIME (Proliferation-Inducing and Migration-Enhancing) technology. As a public-listed company, we will proactively advance efforts to deliver truly effective treatments to patients suffering from cancer worldwide as soon as possible.

For further details, please refer to the "New Listing" page on the website of Japan Exchange Group.

<https://www.jpx.co.jp/listing/stocks/new/index.html>